Central Organization Institute of Legal Education (ILE) • Master Scholarly Repository & Academic Law Journals
Institute of Legal Education

Institute of Legal Education

Premier Scholarly Publishing House, Central Legal Research Repository & Academic Network
Home › Repository › Article Details
ILE-AIT-17372 Indian Journal of Legal Review (IJLR)
✓ Double-Blind Peer Reviewed 🔓 Open Access

SECTION 3(D) AND THE LIMITS OF PATENTABILITY: INDIA’S LEGISLATIVE RESPONSE TO PHARMACEUTICAL EVERGREENING

Author(s): INDIAN JOURNAL OF LEGAL REVIEW
Volume: 4 Issue: 2 Year: 2026 ISSN: 2583-2344 APIS: 3920-0001 Publisher: Institute of Legal Education (ILE)
Recommended Bluebook Citation
INDIAN JOURNAL OF LEGAL REVIEW, SECTION 3(D) AND THE LIMITS OF PATENTABILITY: INDIA’S LEGISLATIVE RESPONSE TO PHARMACEUTICAL EVERGREENING, 4 Indian Journal of Legal Review 2 (2026).

Abstract

SECTION 3(D) AND THE LIMITS OF PATENTABILITY: INDIA'S LEGISLATIVE RESPONSE TO PHARMACEUTICAL EVERGREENING

AUTHOR - BHUMIKA PANDEY, STUDENT AT CHRIST (DEEMED TO BE UNIVERSITY), PUNE, MAHARASHTRA

BEST CITATION – BHUMIKA PANDEY, SECTION 3(D) AND THE LIMITS OF PATENTABILITY: INDIA'S LEGISLATIVE RESPONSE TO PHARMACEUTICAL EVERGREENING, INDIAN JOURNAL OF LEGAL REVIEW (IJLR), 6 (8) OF 2026, PG. 716-727, APIS – 3920 – 0001 & ISSN - 2583-2344

ABSTRACT

One of the most significant and internationally reviewed provisions in the pharmaceutical patenting arena in the world was brought by the Patents (Amendment) Act, 2005 in India, in the form of Section 3(d) of the Patents Act, 1970. The provision was enacted as a direct legislative reaction to the perceived menace of pharmaceutical evergreening and it is categorical in its denying of coverage of patent protection to novel forms of known substances except where a significant enhancement of therapeutic efficacy is proven. The present paper will develop a doctrinal and analytical discussion of Section 3(d) starting with its legislative background of the pre-TRIPS period of the Patents Act, 1970 to the compulsions of the Agreement on Trade-Related Aspects of Intellectual Property Rights and finally its sound jurisprudential interpretation by the Supreme Court of India in Novartis AG v. Union of India. It contends in the paper that Section 3(d) is a reflective, constitutionally acceptable adjustment of the patent law towards promoting the best possible health outcomes rather than gradual pharmaceutical innovation. It also discusses how the provision has helped retain India as the pharmacy of the world, criticisms of the provision by multinational pharmaceutical firms and the United States Trade Representative, and how well the provision balances the flexibilities framework of the TRIPS Agreement. The paper concludes that Section 3(d) is a valid, justified and internationally important tool that other developing countries can contemplate making amendments in their own home based intellectual property systems.

Keywords: Section 3(d), evergreening, TRIPS flexibilities, Novartis v. Union of India, pharmaceutical patent, access to medicines, therapeutic efficacy, compulsory licensing.

← Back to Repository Search